BioSpace

Compass to submit psilocybin depression drug for approval imminently after stock wobbles

Compass Pathways revealed that an FDA filing for COMP360 will be complete “in the next two weeks,” with an expected drug launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilocybin candidate for depression on Monday.

By BioSpace

1 min read
Compass to submit psilocybin depression drug for approval imminently after stock wobbles
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights